2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1631

Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1298

Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH): A Collaborative and Systems-Based Approach to Improve Access to Care

Health Services Research Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 1431

Age and Sex Impacts the Development of Hypersensitivity in the Murine Partial Medial Menisectomy Model of Osteoarthritis

Pain: Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 1325

Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1533

Age Related Disability in Daily Life Should be Considered in Older Than Sixty-Five-Year-Old Rheumatoid Arthritis Patient

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1165

Age-Dependent Effects of HLA-B27/β2m Expression on Host Immunity and the Intestinal Microbiota

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1215

Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1154

Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-α and IFN-α from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1694

All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1758

Alterations in Nuclear Structure Promote Lupus Autoimmunity in a Mouse Model

Systemic Lupus Erythematosus - Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 1132

Altered Histone 3 Dynamics at the Matrix Metalloproteinase 1 (MMP1) Transcription Start Site Contributes to MMP1 Suppression in Betaine Supplemented Synovial Fibroblasts in Rheumatoid Arthritis

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1181

Ambulatory Rheumatology Curriculum: Effect of Fellow Teaching Multimodal Simulation Curriculum Enhancement

Education Poster I

9:00AM-11:00AM: Abstract Number: 1378

AMP-Activated Protein Kinase As an Anti-Inflammatory Target for Methotrexate

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1179

An Evidence-Based Analysis and Revision of a Pediatric Rheumatology Academic Half-Day Program

Education Poster I

9:00AM-11:00AM: Abstract Number: 1457

An Organ Based Diagnostic Approach to Macrophage Activating Syndrome in Children Demonstrates Impaired Reticuloendothelial System Clearance

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].